Literature DB >> 30104291

Interleukin-2 Can Cure Kidney Cancer.

Janice P Dutcher1, Peter H Wiernik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30104291      PMCID： PMC6192664          DOI： 10.1634/theoncologist.2018-0038

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Authors:  Martin E Gore; Clare L Griffin; Barry Hancock; Poulam M Patel; Lynda Pyle; Michael Aitchison; Nicholas James; Roderick T D Oliver; Jozef Mardiak; Tahera Hussain; Richard Sylvester; Mahesh K B Parmar; Patrick Royston; Peter F A Mulders
Journal:  Lancet       Date:  2010-02-10       Impact factor: 79.321

2.  Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?

Authors:  Dhanusha Sabanathan; John J Park; Manuel Marquez; Louise Francisco; Natalie Byrne; Howard Gurney
Journal:  Oncologist       Date:  2017-11-16

3.  Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.

Authors:  David D Stenehjem; Michael Toole; Joseph Merriman; Kinjal Parikh; Stephanie Daignault; Sarah Scarlett; Peg Esper; Katherine Skinner; Aaron Udager; Srinivas Kiran Tantravahi; David Gill; Alli M Straubhar; Archana M Agarwal; Kenneth F Grossmann; Wolfram E Samlowski; Bruce Redman; Neeraj Agarwal; Ajjai Alva
Journal:  Cancer Immunol Immunother       Date:  2016-06-08       Impact factor: 6.968

4.  The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

Authors:  David F McDermott; Su-Chun Cheng; Sabina Signoretti; Kim A Margolin; Joseph I Clark; Jeffrey A Sosman; Janice P Dutcher; Theodore F Logan; Brendan D Curti; Marc S Ernstoff; Leonard Appleman; Michael K K Wong; Nikhil I Khushalani; Leslie Oleksowicz; Ulka N Vaishampayan; James W Mier; David J Panka; Rupal S Bhatt; Alexandra S Bailey; Bradley C Leibovich; Eugene D Kwon; Fairooz F Kabbinavar; Arie S Belldegrun; Robert A Figlin; Allan J Pantuck; Meredith M Regan; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

5.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Authors:  G Fyfe; R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; A C Louie
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

6.  High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.

Authors:  S Chow; V Galvis; M Pillai; R Leach; E Keene; A Spencer-Shaw; A Shablak; J Shanks; T Liptrot; F Thistlethwaite; R E Hawkins
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.